Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
CooperCompanies (COO): Strong Margins & Product Mix Intact—Does a Soft Start to 2025 Change the Thesis? Examining Global Contact Lens Market Trends & Key Growth Drivers!
CooperCompanies delivered 4% YoY revenue growth to $965M, narrowly missing expectations, leading to a 5% after-hours decline in shares. CooperVision (CVI) grew 4% YoY (+6% organic), with strong toric and multifocal demand (+10%) and daily silicone hydrogel lenses (+9%) offsetting APAC softness (-2% YoY) tied to China. Myopia management continued scaling (+20% YoY), with MiSight up 27%. CooperSurgical (CSI) posted 3% growth, with labor & delivery and gynecological products outperforming, though fertility growth lagged at 1% due to Q4 capital pull-forward. Margins improved, with gross margin up 140bps to 68.7% on manufacturing efficiencies and product mix, supporting an EPS guidance lift to $3.94-$4.02. With MyDay toric and multifocal supply constraints easing earlier than expected, CVI’s organic growth should reaccelerate in 2H25, particularly as private label demand strengthens. CSI’s fertility segment, while soft in Q1, is positioned for sequential improvement, and Paragard (+12% YoY) remains a growth driver despite upcoming competition. Management reaffirmed FY25 sales guidance of $4.08-$4.16B, with FX movements providing potential EPS upside. Can Cooper sustain its growth momentum and margin expansion in the face of APAC softness and fertility volatility, or does the market’s reaction signal concerns about a more prolonged demand slowdown?